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Background: Breast cancer is the leading cancer among women, and early diagnosis is essential for future prognosis.
Evidence from mainly cross-sectional US studies with self-reported exposure and outcome found positive association
of body mass index (BMI) with non-participation in mammographic screening, but hardly addressed the influence
of potential effect-modifiers. We studied the association between objective measures of BMI and participation in
mammographic screening in a Danish prospective cohort, and explored the influence of menopausal status, hormone
therapy (HT), previous screening participation, and morbidities on this relationship.
Methods: A total of 5,134 women from the Diet, Cancer, and Health cohort who were invited to population based
mammographic screening in Copenhagen were included in analysis. Women were 50–64 years old at inclusion
(1993–97) when their height and weight were measured and covariates collected via questionnaire. Odds ratios
(OR) and 95% confidence intervals (CI) for the association between BMI and mammographic screening participation
were estimated by logistic regression, adjusted for other breast cancer risk factors and morbidities. Effect modification
was evaluated by an interaction term and tested by Wald test.
Results: Underweight (BMI < 18.5 kg/m2, OR: 95% CI; 2.24: 1.27-3.96) and obese women of class II (BMI 35–40 kg/m2,
1.54: 0.99-2.39) and III (BMI≥ 40 kg/m2, 1.81: 0.95-3.44) had significantly higher odds of non-participation than women
with normal weight. This association was limited to postmenopausal women (Wald test p = 0.08), with enhanced
non-participation in underweight (2.83: 1.52-5.27) and obese women of class II and III (1.84: 1.15-2.95; 2.47: 1.20-5.06) as
compared to normal weight postmenopausal women. There was no effect modification by HT, previous screening
participation, or morbidities, besides suggestive evidence of enhanced non-participation in diabetic overweight
and obese women.
Conclusions: Underweight and very obese postmenopausal women were significantly less likely to participate in
mammographic screening than women with normal weight, while BMI was not related to screening in premenopausal
women. Effect of BMI on mammographic screening participation was not significantly modified by HT, previous
screening participation, or morbidities.
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Breast cancer is the leading cancer type and cause of
death from cancer among women in the Western world
[1]. Diagnosis of breast cancer at an early stage is im-
portant for future prognosis [2]. Mammographic screen-
ing is an essential public health intervention in detecting
early stage breast tumors, when treatment is more suc-
cessful and survival more favorable [3]. High participation
rate is paramount for the effectiveness of mammographic
screening with participation rates above 70% being accept-
able, and 75% desirable [3].
Obesity is positively associated with breast cancer
risk in postmenopausal women [4], and possibly in
premenopausal women when accounting for mammo-
graphic density [5]. Obesity is also related to poor
breast cancer prognosis [6]. Recent reviews [7-9] of
mainly cross-sectional studies suggested that obesity is
associated with non-participation in mammographic
screening, in particular among Caucasian women, but
not among black American women. This implies that
cultural differences in the perception of obesity seem to
have an impact on their compliance with organized
mammographic screening [7,8].
Current evidence on the relationship between body
mass index (BMI) and participation in mammographic
screening was mainly conducted in US populations, with
high rates of opportunistic screening, and with profound
socio-economic and health care access disparities that
might confound the findings, since obesity is more
prevalent among women with low socio-economic status
[10]. Furthermore, existing studies mostly evaluated risk
of non-participation based on self-reports of BMI and
screening behavior, potentially masking effects due to
recall and misclassification bias [11].
We studied an association between BMI and mammo-
graphic screening participation in a cohort of Danish
women with objectively measured BMI and screening
participation and with equal and free access to organized
non-profit mammographic screening. We furthermore
assessed whether menopausal status, previous mammo-
graphic screening participation, hormone replacement
therapy (HT) use, or morbidities including stroke, myo-
cardial infarction (MI), hypertension, hypercholesterol-
emia, or diabetes confounded or modified this association.
Methods
The Danish diet, cancer, and health cohort
The Danish Diet, Cancer, and Health cohort (DCH) is
an associated cohort of the European Prospective Inves-
tigation into Cancer and Nutrition, described elsewhere
[12]. Briefly, 79,729 women aged 50–64 years, born in
Denmark, living in the large metropolitan areas of
Copenhagen or Aarhus, and free of all cancer were
invited, and 29,875 (37%) agreed to participate in thecohort [12]. Of total of 29,875 women in the DCH
cohort, 21,154 lived in greater Copenhagen area, and
less than a half of these lived in Copenhagen municipal-
ity (inner Copenhagen), where mammographic screen-
ing was in place since 1991 targeting women aged 50–
69 years, and thus providing overlap with DCH cohort
women, who were recruited between 1993 and 1999,
when they were aged 50–65 years. Anthropometric
measures were obtained by trained professionals at
cohort baseline between 1993 and 1997, when also self-
reported information on reproductive and life style
exposures and morbidities were obtained via question-
naire. Measures of standing height and weight were
recorded to the nearest 0.1 cm and 0.1 kg with partici-
pants wearing no shoes. BMI was calculated as weight
divided by height in meters squared (kg/m2). BMI was
defined according to the standard cutoff points by the
World Health Organization (WHO) in categories of
underweight: < 18.5, normal weight: 18.5-24.9, over-
weight: 25.0-29.9, obese class I: 30.0-34.9, obese class II:
35.0-39.9, and obese class III: > 40 kg/m2. Other covari-
ates were self-reported and included menarche age,
parity, age at first childbirth, breastfeeding, oral contra-
ceptive use, HT use, menopausal status, menopausal
age, education, smoking, alcohol use, and sports, de-
scribed in Table 1. Self-reported morbidity with angina
pectoris, diabetes, hypercholesterolemia, hypertension,
MI, and stroke were defined as either having diagnoses or
receiving medication for the specific disease. Premeno-
pausal status was defined by no current hormone use and
at least one menstrual bleeding within the last year. If in-
formation was not available on these variables, or if
women had a hysterectomy with unknown age for meno-
pause, then premenopausal status was defined by age ≤
55 years at baseline. Postmenopausal status was defined by
current HT use, bilateral oophorectomy, no menstrual
bleeding within the last year and intact uterus, self-
reported age of menopause, or age > 55 years, if informa-
tion was not available on any of these variables.
Copenhagen mammographic screening program
Biennial mammographic screening was first introduced
in Denmark in the municipality of Copenhagen in April
1991, free of charge to all women aged 50–69 years.
Opportunistic mammographic screening is and was very
limited in Denmark [13]. The central population register
was used to define the target population for mammo-
graphic screening, contributing information on personal
identification number (ID-number) issued to all residents
of Denmark, migration, and vital status [14]. Targeted
women were invited to screening if they: a) had not actively
declined participation in previous screening rounds, b) did
not have breast surgery within the past 18 months, c) were
not bilateral mastectomized or had breast implants, where
Table 1 Study population characteristics for 5,134 Danish women by BMI. Danish Diet, Cancer, and Health Cohort
(1993–2008)
Body mass index*
Characteristics Total Underweight Normal Overweight Obese I Obese II Obese III
N women 5,134 74 2,381 1,772 657 182 68
N (%) non-participants in screening 557 (10.9) 17 (23.0) 285 (12.0) 152 (8.6) 62 (9.4) 28 (15.4) 13 (19.1)
N (%) Previously screened 3,914 (76.2) 59 (79.7) 1,750 (73.5) 1,387 (78.3) 517 (78.7) 149 (81.9) 52 (76.5)
Mean (SD) BMI, kg/m2 26.0 (4.7) 17.5 (0.9) 22.4 (1.6) 27.1 (1.4) 31.8 (1.3) 37.2 (1.4) 43.2 (3.6)
Mean (SD) birth cohort, year 1938 (4.5) 1936 (4.7) 1938 (4.5) 1937 (4.6) 1937 (4.5) 1937 (4.5) 1938 (4.6)
Mean (SD) age at screening, years 56.4 (4.5) 57.7 (4.6) 55.9 (4.4) 56.8 (4.5) 56.8 (4.5) 57.2 (4.4) 56.5 (4.5)
Mean (SD) age at menarche, years 13.6 (1.7) 14.1 (1.6) 13.8 (1.6) 13.5 (1.7) 13.3 (1.7) 13.4 (1.9) 13.1 (2.0)
Mean (SD) age at first birth, years 22.6 (4.2) 23.1 (4.0) 23.2 (4.1) 22.3 (4.2) 22.2 (4.4) 21.5 (3.7) 22.1 (3.7)
Mean (SD) age at menopause, years 48.4 (5.6) 45.9 (7.2) 48.5 (5.5) 48.4 (5.6) 48.6 (5.5) 49.0 (5.2) 47.4 (5.7)
N (%) basis school 1,194 (23.3) 14 (18.9) 460 (19.3) 438 (24.7) 206 (31.4) 57 (31.3) 19 (27.9)
N (%) higher education, 1–2 years 2,053 (40.0) 35 (47.3) 961 (40.4) 714 (40.3) 245 (37.3) 67 (36.8) 31 (45.6)
N (%) higher education, 3–4 years 1,228 (23.9) 15 (20.3) 586 (24.6) 424 (23.9) 144 (21.9) 46 (25.3) 13 (19.1)
N (%) higher education, ≥5 y. 659 (12.8) 10 (13.5) 374 (15.7) 196 (11.1) 62 (9.4) 12 (6.6) 5 (7.4)
N (%) postmenopausal 4,114 (80.1) 61 (82.4) 1,854 (77.9) 1,459 (82.3) 537 (81.7) 153 (84.1) 50 (73.5)
N (%) ever used HRT 2,097 (40.8) 32 (43.2) 976 (41.0) 775 (43.7) 245 (37.3) 54 (29.7) 15 (22.1)
N (%) nulliparous 549 (10.7) 15 (20.3) 269 (11.3) 183 (10.3) 59 (9.0) 15 (8.2) 8 (11.8)
N (%) 1–2 children 2,034 (39.6) 32 (43.2) 991 (41.6) 682 (38.5) 233 (35.5) 70 (38.5) 26 (38.2)
N (%) 3–4 children 1,925 (37.5) 19 (25.7) 882 (37.1) 683 (38.6) 248 (37.7) 72 (39.6) 21 (30.9)
N (%) ≥5 children 626 (12.2) 8 (10.8) 239 (10.0) 224 (12.6) 117 (17.8) 25 (13.7) 13 (19.1)
N (%) ever breastfed 4,228 (82.4) 53 (71.6) 1,945 (81.7) 1,494 (84.3) 538 (81.9) 150 (82.4) 48 (70.6)
N (%) ever used oral contraceptives 2,832 (55.2) 38 (51.4) 1,359 (57.1) 989 (55.8) 334 (50.8) 84 (46.2) 28 (41.2)
N (%) never smokers 1,913 (37.3) 16 (21.6) 796 (33.4) 688 (38.8) 297 (45.2) 86 (47.3) 30 (44.1)
N (%) current smokers 2,083 (40.5) 49 (66.2) 1,088 (45.7) 651 (36.7) 224 (34.1) 47 (25.8) 24 (35.3)
N (%) past smokers 1,138 (22.2) 9 (12.2) 497 (20.9) 433 (24.5) 136 (20.7) 49 (26.9) 14 (20.6)
N (%) alcohol abstainers 228 (4.4) 4 (5.4) 101 (4.2) 61 (3.4) 34 (5.2) 16 (8.8) 12 (17.6)
N (%) alcohol occasionally, monthly 1,607 (31.3) 23 (31.1) 645 (27.1) 559 (31.6) 261 (39.7) 89 (48.9) 30 (44.1)
N (%) alcohol≤ 4 units/week 2,165 (42.2) 24 (32.4) 1,028 (43.2) 778 (43.9) 256 (39.0) 58 (31.9) 21 (30.9)
N (%) alcohol≥ 5 units/week 1,134 (22.1) 23 (31.1) 607 (25.5) 374 (21.1) 106 (16.1) 19 (10.4) 5 (7.4)
N (%) participates in sport, weekly 2,543 (49.5) 29 (39.2) 1,251 (52.5) 892 (50.3) 276 (42.0) 69 (37.9) 26 (38.2)
N (%) angina pectoris 132 (2.6) 2 (2.7) 40 (1.7) 54 (3.0) 30 (4.6) 4 (2.2) 2 (2.9)
N (%) diabetes 92 (1.8) 0 (0.0) 25 (1.0) 25 (1.4) 28 (4.3) 8 (4.4) 6 (8.8)
N (%) hypercholesterolemia 307 (6.0) 4 (5.4) 113 (4.8) 116 (6.6) 53 (8.1) 16 (8.8) 5 (7.4)
N (%) hypertension 964 (18.8) 12 (16.2) 311 (13.1) 354 (20.0) 185 (28.2) 75 (41.2) 27 (39.7)
N (%) myocardial infarction 58 (1.1) 3 (4.0) 17 (0.7) 22 (1.2) 11 (1.7) 2 (1.1) 3 (4.4)
N (%) stroke 69 (1.3) 5 (6.8) 16 (0.7) 32 (1.8) 9 (1.4) 5 (2.7) 2 (2.9)
*Underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), Obese class I (30.0-34.9 kg/m2), Obese class II (35.0-39.9 kg/m2),
Obese class III (≥40.0 kg/m2). HRT – hormone replacement therapy; BMI – body mass index.
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minder was mailed to the women if they failed to respond
to an invitation. The Copenhagen mammographic screen-
ing program performs well according to international
prognostic indicators [16], with participation rate of
71% (1991–2001). We used data from the Copenhagenmammographic screening register from 1 April 1991
until 14 April 2008, containing ID-number for each
women and bi-annual sequence of invitation dates,
screening dates, history of reminders, and screening
outcome. To facilitate prospective analyses of an effect of
BMI on later participation in mammographic screening,
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DCH cohort baseline date (1993–1997). As women are
invited to screening every two years, maximum time
between cohort baseline and screening invitation was
2 years. The outcome was thus dichotomous indicator of
non-participation (women who were invited but did not
participate) and participation (women who were invited
and attended mammographic screening). Furthermore, we
defined previously screened (1) as women who partici-
pated in mammographic screening before cohort baseline
(1993–97), and firstly screened (2) as women who did not
participate in screening before cohort baseline, and have
thus participated in mammographic screening for the first
time after cohort baseline (1993–97).
Statistical analysis
Logistic regression was performed to estimate the risk of
non-participation with respect to BMI, with increasing
level of adjustment for potential confounders: model 1:
crude; model 2: adjusted for age and birth cohort (modeled
as continuous covariates); model 3: further adjusted for
menarche age, parity, age at first childbirth, breastfeed-
ing, oral contraceptives, HT use, menopausal status,
menopausal age, education, smoking, alcohol use, and
sports (modeled as categorical covariates); model 4: fur-
ther adjusted for angina pectoris, diabetes, hypercholes-
terolemia, hypertension, myocardial infraction, and
stroke (modeled as categorical covariates). Effects are
presented as odds ratios (OR) and 95% confidence inter-
vals, with two-sided tests at the 5%-significance level.
Chi-square trend test was further calculated to estimate
potential dose–response effects across obese class I-III
categories in a sensitivity analysis excluding under-
weight women. An effect modification of an association
between BMI and screening participation with meno-
pausal status, HT use, previous screening participation,
and comorbidity was evaluated by introducing an inter-
action term and tested by Wald test. Data were analyzed
using SAS version 9.2 (SAS Institute, Cary NC, USA).
Informed consent was obtained from all study partici-
pants to use survey data and search information from
medical registers14. The study was entirely a register
based study approved by the Danish Data Inspection
Agency by Danish law serving as ethical approval of
register-based research.
Results
Of 29,875 women in the DCH cohort, 21,154 lived in
greater Copenhagen area, and of these, 7,507 who lived
in Copenhagen municipality and fulfilled criteria, were
invited to Copenhagen mammographic screening. Of
these, 547 women were excluded as they were invited
to screening only before DCH baseline (no invitations
to screening after baseline) and 1,826 due to missinginformation on covariates, of these only 15 women were
excluded due to missing data on BMI. Excluded 2,373
women did not differ from participating 5,134 women
with respect to screening attendance, screening age,
educational level, BMI, and smoking status, but were
significantly more likely postmenopausal, parous, ever
users of oral contraceptives and HT, and heavy drinkers
(data not shown).
Of 5,134 women included in main analyses, 4,577
(89.1%) participated in screening (Table 1). Median BMI
was 25.2 kg/m2, and mean time from measured BMI to
mammographic screening invitation was 1.3 years (SD
1.5). Compared to normal weight women, obese women
(class I-III) were less educated and more likely to be post-
menopausal, never users of HT, parous, never smokers,
alcohol abstainers, and physically inactive (Table 1).
The crude (Model 1) and fully adjusted OR (Model 4)
for non-participation in mammographic screening for
underweight as compared to women with normal BMI
was 2.19 (1.26-3.82) and 2.24 (1.27-3.96), respectively
(Table 2). Results were robust to adjustment for covari-
ates, thus Model 4 is considered main model for which
the results are presented in the paper. Overweight
women were significantly more likely to participate in
mammographic screening than women with normal
weight with OR of 0.75 (0.61-0.93), as were women in
obese category I, but not statistically significantly (0.85;
0.63-1.15). However, most obese women (class II and
III) had a borderline significantly higher odds of non-
participation of 1.54 (0.99-2.39) and 1.81 (0.95-3.44),
respectively. There was a significant trend (p < 0.001) of
increasing non-participation with increasing categories
of obesity in sensitivity analysis excluding underweight
women.
Test for interaction between BMI and menopausal
status was borderline significant (p = 0.08), indicating en-
hanced associations in post- and none in premenopausal
women. Higher odds of non-participation in postmeno-
pausal underweight (2.83; 1.52-5.27) and obese women
of class II and III (1.84; 1.15-2.95 and 2.47; 1.20-5.06)
were observed compared to postmenopausal women
with normal weight (Table 3), with statistically significant
trend (p = 0.0002) of increasing non-participation with in-
creasing BMI. BMI was not associated with screening
participation among premenopausal women (Table 3).
There was no significant effect-modification by HT (p =
0.99), or by angina pectoris (p = 0.95), hypercholesterol-
emia (p = 0.86), hypertension (p = 0.48), myocardial in-
farction (p = 0.95), or stroke (p = 0.97). Interaction with
previous screening participation was not statistically sig-
nificant (p = 0.15), but indicated that non-participation in
obese women was limited to those who previously partici-
pated in screening (overweight: 0.70; 0.54-0.91, obese class
I: 1.01; 0.71-1.42, obese class II: 1.86; 1.14-3.04, and obese
Table 2 Association of BMI with mammographic screening non-participation in the Diet, Cancer, and Health Cohort
Model 11 Model 22 Model 33 Model 44
BMI BMI value N (%) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Underweight <18.5 74 (1.4) 2.19 (1.26-3.82) 2.39 (1.37-4.18) 2.23 (1.27-3.95) 2.24 (1.27-3.96)
Normal range 18.5-24.9 2,381 (46.4) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
Overweight 25.0-29.9 1,772 (34.5) 0.69 (0.56-0.85) 0.71 (0.58-0.87) 0.74 (0.60-0.92) 0.75 (0.61-0.93)
Obese class I 30.0-34.9 657 (12.8) 0.77 (0.57-1.02) 0.79 (0.59-1.06) 0.83 (0.62-1.12) 0.85 (0.63-1.15)
Obese class II 35.0-39.9 182 (3.6) 1.34 (0.88-2.04) 1.39 (0.91-2.12) 1.47 (0.95-2.27) 1.54 (0.99-2.39)
Obese class III >40.0 68 (1.3) 1.74 (0.94-3.22) 1.80 (0.97-3.35) 1.76 (0.93-3.32) 1.81 (0.95-3.44)
1Model 1: Crude. 2Model 2: Adjusted for age and birth cohort. 3Model 3: Adjusted for age, birth cohort, education, menarche age, menopausal status, menopausal
age, hormone replacement therapy use, oral contraceptives use, parity, age first childbirth, breastfeeding, smoking, alcohol, and sports.
4Model 4: Adjusted for model 3 + comorbidity.
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as compared to obese women participating in their first
screening (overweight: 0.89; 0.60-1.30, obese class I: 0.47;
0.23-0.94, obese class II: 0.74; 0.24-2.34, and obese class
III: 1.11; 0.29-4.35, all compared to normal weight).
However, underweight women had high risk of non-
participation in both, their first (2.09; 0.61-7.17) and
subsequent screening (2.30; 1.19-4.45). Interaction with
diabetes was not statistically significant (p = 0.34), due to
small numbers, but diabetic overweight women had sev-
eral fold higher odds of non-participation (overweight:
1.70; 0.12-23.94, obese class I: 4.38; 0.35-54.71, obese class
II: 2.72; 0.10-74.66, and obese class III: 28.81; 1.37-604.02,
all compared to normal weight) than overweight non-
diabetic women (overweight: 0.74; 0.60-0.90, obese class I:
0.82; 0.61-1.11, obese class II: 1.58; 1.02-2.45, and obese
class III: 1.58; 0.79-3.18, all compared to normal weight).Discussion
We found lower mammographic screening participation
among underweight and obese as compared to normal
weight women with a dose–response relationship among
obese class I-III. These associations were limited to post-
menopausal women, and were robust to adjustment for
other breast cancer risk factors and morbidities.Table 3 Association of BMI with mammographic screening no
and Health Cohort
Premenopausal women (n =
BMI BMI value N (%) OR (
Underweight <18.5 13 (1.3) 0.85
Normal range 18.5-24.9 527 (51.7) 1.00
Overweight 25.0-29.9 313 (30.7) 0.79
Obese class I 30.0-34.9 120 (11.8) 0.45
Obese class II 35.0-39.9 29 (2.8) 0.41
Obese class III >40.0 18 (1.8) 0.63
1Adjusted for age, birth cohort, education, menarche age, hormone replacement th
smoking, alcohol, sports, and comorbidity.This is the first study on the association between BMI
and mammographic screening participation in Denmark,
where, as opposed to US, free, tax subsidized, and
universal access to healthcare represents the core values
in public health strategies, and where background rates
of opportunistic mammographic screening are low. In
Denmark, health care is free to all citizens, and mammo-
graphic screening is recommended by health authorities,
and offered free of charge, with a personal invitation, to
all women in age 50–69. In contrast, in US, health care
is largely privatized and access and cost of mammo-
graphic screening differs by health insurance package a
woman has, and if has health insurance. Thus, access to
mammographic screening is different in Denmark and
USA. Our study population consisted of a homogenous
population of Caucasian women with equal and free
access to health care services.
The results of our study add new insight to current
evidence, which is mainly based on cross-sectional studies
from US populations [17-30] with profound socio-
economic and racial disparities in health care access,
and high rates of mammographic opportunistic screening.
Thus, results from US studies are vulnerable to selection
bias and residual confounding from uncontrolled socio-
economic barriers to screening. The only study conducted
in a population with free and universal access to healthn-participation by menopausal status in the Diet Cancer,
1,020) Postmenopausal women (n = 4,114)
95% CI)1 N (%) OR (95% CI)1
(0.18-4.15) 61 (1.5) 2.83 (1.52-5.27)
(ref.) 1,854 (45.1) 1.00 (ref.)
(0.51-1.23) 1,459 (35.5) 0.73 (0.57-0.93)
(0.20-0.99) 537 (13.0) 0.98 (0.70-1.37)
(0.09-1.92) 153 (3.7) 1.84 (1.15-2.95)
(0.13-3.16) 50 (1.2) 2.47 (1.20-5.06)
erapy use, oral contraceptives use, parity, age at first childbirth, breastfeeding,
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Canadian study by Mitchell et al. [26] who found no
association between BMI and mammographic screen-
ing attendance. However, Mitchel et al. [26], as well as
most other existing studies [17-25,27-30], relied on
self-reports of BMI [17-25,27-30], which could attenu-
ate associations, since obese women tend to underre-
port their actual weight [11,31,32].
The current study benefited from objectively measured
BMI by health care professionals [12]. Only study by
Chang et al. [18] in part used objectively measured BMI
and chart extractions on mammographic screening par-
ticipation in 2,832 women from the American Veterans
Health Administration registry, and found no evidence
of an association between BMI ≥ 30 and mammographic
screening participation. Furthermore, majority of previ-
ous studies [17,19-24,26-30] were limited by self-reports
on screening participation, where recall and misclassifi-
cation bias cannot be ruled out [11].
We found a significant positive association between
obesity and non-participation, in accordance with majority
of existing studies, which were cross-sectional, assessing
self-reported BMI typically to screening participation in
last 2 years. We have furthermore, detected significant
dose–response relationship between obesity and non-
participation with a significant higher probability of non-
participation with increasing obesity class, as reported
earlier in some [19,22,24,25,27-30], but not all [17,18,
20,23,26] studies. Cohen et al. [19] found a 30% significant
increased risk of non-participation in mammographic
screening among obese women of class III in 6,304
Caucasian women older than 42 years in the Southern
Community Cohort Study. Ferrante et al. [22] found a
50% significantly increased risk of non-participation in
mammographic screening in most obese of 7,544
women aged 40–74 years from the 2000 National Health
Interview Survey. Wee et al. [29] found a 6-17% borderline
significantly increased risk of non-participation in mam-
mographic screening among obese women of class I-III in
5,277 Caucasian women aged 50–75 years from the 1998
National Health Interview Survey (NHIS). This finding
was partly confirmed by Zhu et al. [30] in the 2000 NHIS,
where a borderline significant 40% increased risk of
non-participation in mammographic screening was
found for the most obese (class III) of 7,692 Caucasian
women aged 40–80 years, but failing to detect a dose–
response relationship. Ostbye et al. [27] found a 27-40%
significant increased risk of non-participation in mam-
mographic screening among obese women (class I-III)
in a cohort of 4,439 Caucasian women aged 50–64 years
from the Health and Retirement Study.
The U-shaped association between BMI and mammo-
graphic screening participation, with high risk of non-
participation in underweight and very obese women, wasrestricted to postmenopausal women only. BMI did not
play a role in screening participation in premenopausal
women. Cohen et al. [19] was the single study conducting
analysis for effect-modification by menopausal status, and,
in contrast to us, found no evidence of effect modification.
Mammographic screening attendance in underweight
women has received less attention in literature than
screening in overweight and obese women. Higher prob-
ability of morbidity in underweight compared to normal
weight women might preclude underweight women from
mammographic screening participation, which compli-
cates unbiased estimation of their probability of nonpar-
ticipation in mammographic screening in relation to
underweight. Few existing studies reported either no
association with27;29 or increased non-participation in
[17,20,24,30] mammographic screening among under-
weight women. Study by Chang et al. [18] found a signi-
ficantly increased non-participation among underweight
compared to normal weight in the Medicare population,
whereas no association was found in the Veterans Health
Administration population with objectively measured ex-
posure and outcome information. In our study, we found
a strong and statistically significant positive association be-
tween underweight and non-participation, even stronger
than risk for non-participation related to obesity. The risk
of nonparticipation in underweight women was not modi-
fied by previous screening participation. Furthermore, we
found novel results that underweight was related to non-
participation only in postmenopausal women, as no previ-
ous studies explored effect-modification by menopausal
status in association between BMI and underweight.
The lower screening attendance among underweight
and obese women could be a result of underlying illness
and poorer general health than in women with normal
weight, where absence from screening could be due to
competing health burden and managing of existing
disease. Morbidity with cardiovascular disease (angina
pectoris, MI, hypertension, hypercholesterolemia) did
not in our data explain absence from screening in under-
weight or obese women. There were no underweight
women with diabetes in this study, but we have found
two- to twenty- fold higher non-participation in mam-
mographic screening among both overweight and obese
diabetic, than in non-diabetic overweight and obese
women. This finding indicates that diabetes may be an
important barrier to screening, possibly stronger than
obesity. Perhaps, diabetes may present competing health
burden due to which diabetic women lack resources to
go attend screening. These observations were based on
limited number of cases, resulting in statistically insig-
nificant p-value for interaction (0.34) and have never been
reported before, and thus demand replication in other
studies. However, in the face of obesity and diabetes epi-
demic worldwide, and being that obesity and diabetes both
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findings indicate that targeted efforts in increased infor-
mation about screening in diabetic women may have sig-
nificant impact on their breast cancer prognosis.
Most of available evidence on association of mammo-
graphic screening participation with BMI is based on
self-reported information on both exposure and out-
come in cross-sectional design [34]. The study by Ostbye
et al. [27] is only study with prospectively obtained self-
reported BMI and screening information in-between two
waves of cohort follow-up. Our study is thus to date the
largest prospective cohort study presenting results on the
association between objectively measured BMI exposure
and subsequent mammographic screening participation.
Next to obesity, a complex mix of factors relating to
health care systems, patients, and providers could deter-
mine if women abstain from mammographic screening
[7,8]. A higher mammographic screening participation
rate in rural compared to urban areas of Denmark and
an age-adjusted U-shaped association between women’s
educational level and socio-economic status and risk of
non-participation was reported earlier [35-38]. Contrary
to the US, Denmark has free access to health care
services, including mammographic screening irrespective
of socio-economic status, which is an established pre-
dictor for participation [8,39]. Cultural differences in the
perception of obesity may also have an impact on
women’s body-perception and compliance with orga-
nized mammographic screening [7,8]. Obesity rates are
higher in USA than Denmark, and thus, perhaps general
perception and acceptance of obesity, is higher in US,
including health care system, which is likely more used
to and prepared for dealing with obese persons. Still,
obesity is observed to be related to non-participation in
US and Denmark alike, possibly confirming earlier studies
that the slim body ideal and negative perception of obesity
in western cultures might predict non-participation in
mammographic screening, in USA and Denmark alike
[7,8]. A qualitative study by Friedman et al. [40] on weight
barriers to mammographic screening proposed that nega-
tive attitudes and insensitive comments about weight from
providers, medical equipment too small for obese,
embarrassment of obesity during examination, fear of
pain during examination, fear of cancer, competing de-
mands on their time, and an impression of low breast
cancer risk acted as possible barriers to screening in the
studied population of obese women. We found that
obese women, who previously participated in screening,
seemed to have higher risk of non-participation in sub-
sequent screening, indicating hypothetically that nega-
tive experience at a previous screening, such as pain or
discomfort, may be a barrier for later participation. The
same pattern was not observed for underweight women,
who exhibited consistently high risk of non-participationin mammographic screening, unexplained by morbidities
or previous participation in screening this study.
Since obesity is a predictor of breast cancer incidence,
especially in postmenopausal women, breast cancer mani-
festation, and prognosis [6,41], it is important to identify
barriers to mammographic screening [4]. Early detection
by mammographic screening has been associated with im-
proved prognostic tumor characteristics [16], and reduced
morbidity and mortality from breast cancer [7,8,16,42]. In-
creased participation rates in mammographic screening
among obese women, and possibly diabetic women, may
therefore possibly be expected to result in reduced mor-
bidity and mortality in this population.
Strength of our study is the prospective design with
objectively measured BMI prior to register-based invita-
tion to mammographic screening, in contrast to majority
of existing studies of cross-sectional design with self-
reports limiting causal inferences to determine causality.
Objectively measured data on BMI and screening par-
ticipation limit possibility of exposure misclassification,
recall and information bias. As documented, DCH is not
representative of the general population as participants
had higher educational and socioeconomic status, and
were likely more health awareness than non-participants
[12]. Similarly, women in this study a higher participa-
tion of 89% as compared to an expected participation
rate of 71% in Copenhagen in this period (1991–2001).
Another major limitation was exclusion of 32% (2,373)
of the eligible women (5,134) due to missing information
on screening date or covariates. However, only 15 women
were excluded for missing BMI measurements, and
excluded 2,373 women did not differ from participating
5,134 women with respect to screening attendance,
screening age, educational level, BMI, and smoking status,
but were significantly more likely postmenopausal, parous,
ever users of oral contraceptives and HT, and heavy
drinkers (data not shown). As excluded women were not
different from participating women with respect to BMI,
our main exposure of interest, or screening participation,
our outcome, missing data were not likely to pose major
bias in our results on association between BMI and
screening participation. Still, due to the fact that women
in the study were more likely parous, heavy drinkers, and
users of HT and OC than excluded women, the weakness
is that our study sample may not be representative of the
excluded women and general population. We used educa-
tional status as a proxy for socio-economic status, and
educational status was an independent significant pre-
dictor for mammographic screening participation in our
data. However, since ORs were robust to adjustment for
all covariates in the multivariate models, further adjust-
ment for socio-economic status would likely not impact
the current results. Covariate information was based
on self-reports, implying possible misclassification of
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most likely be non-differential, since covariate data were
obtained prospectively and independently of the informa-
tion on the outcome of this study.
The higher probability of non-participation among
underweight and obese women, and possibly in particu-
lar obese women with diabetes, could implicate later
diagnosis, more advanced clinical stages of disease at
diagnosis, and poorer morbidity and mortality [3]. Our
findings could therefore have important public health
implications, because obese post-menopausal women
and diabetics have an established higher breast cancer
risk [33,34], and since mammographic density, a strong
predictor for breast cancer risk [43] inversely associated
with BMI [4], tend to be higher among leaner women.
Targeted information about screening in these groups of
women may improve their breast cancer prognosis.
Conclusions
Our study indicated a higher probability of non-
participation among postmenopausal underweight and
obese women as compared to women with normal weight,
whereas no association was found for premenopausal
women. Furthermore, we found a suggestive evidence of
relevance of diabetes as a barrier to screening in over-
weight and obese women, although based on small num-
bers should be replicated in larger sized future studies.
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